Autism Spectrum Disorder affects over five million people in the European Union. Currently, there are no effective drug treatments for the core symptoms. In this project, the partners aim to make substantial leaps in understanding the underlying mechanisms of the disease and develop objective outcome measures that can be used in trials for new medicines.
The project is led by Kings College London and has 48 other partners in 14 countries, including Noldus.
Role of Noldus
In close cooperation with Demcon, we will develop a smart baby suit which measures the activities of babies at risk of autism, 24/7 in the home environment and securely transmits the data to the researchers’ lab. With current techniques, the babies have to be brought into the lab, which means that their behavior will not be natural and that measurements will be for relatively short periods of time. With the new techniques that we will develop, researchers will be able to get much better insights into the behavior of the babies.
Furthermore, we will also try out the prototype of the MutualGazeReader which we developed in the iCare project.
AIMS-2-TRIALS is funded as part of the Innovative Medicines Initiative (IMI), part of the European Union's Horizon 2020 program. IMI is the European Commission's scheme for supporting precompetitive and public-private collaboration in the pharmaceutical industry.